Medical therapy for ulcerative colitis 2004

Stephen B. Hanauer*

*Corresponding author for this work

Research output: Contribution to journalArticlepeer-review

146 Scopus citations


There continue to be evolutionary changes In the management of ulcerative colitis despite the fact that, aside from a variety of aminosalicylate formulations, no new therapies have been approved over the past few decades. Nevertheless, debates continue regarding the optimization of treatment with aminosalicylates and the short- and long-term benefits of immunomodulation in ulcerative colitis. This article focuses on the most recent clinical studies pertaining to the management of ulcerative colitis and explores both the advances and controversies pertaining to aminosalicylate therapy, corticosteroids, cyclosporine, and the purine antimetabolites. Novel therapeutic approaches-including preliminary experience with biological therapies directed at tumor necrosis factor and other cytokines, adhesion molecules, growth factors, and probiotics-will be reviewed. Recent data regarding potential chemoprevention in long-standing ulcerative colitis and management of postoperative complications and pouchitis will also be discussed.

Original languageEnglish (US)
Pages (from-to)1582-1592
Number of pages11
Issue number6
StatePublished - Jun 2004

ASJC Scopus subject areas

  • Gastroenterology
  • Hepatology


Dive into the research topics of 'Medical therapy for ulcerative colitis 2004'. Together they form a unique fingerprint.

Cite this